

1 ***Mycobacterium tuberculosis*-specific T cell responses are impaired during late**
2 **pregnancy with elevated biomarkers of tuberculosis risk postpartum**

3
4 **Authors:** Aparajita Saha^{1,2}, Jaclyn Escudero², Troy Layouni³, Barbra Richardson^{2,4}, Sharon
5 Hou², Nelly Mugo⁵, Andrew Mujugira^{2,6}, Connie Celum^{1,2,7}, Jared M. Baeten^{2,8}, Jairam
6 Lingappa^{1,2,4}, Grace C. John-Stewart^{1,2,7,9}, Sylvia M. LaCourse^{1,2*}, Javeed A. Shah^{1,2,3*}.

7 *Both authors contributed equally

8
9 **Affiliations:**

10 ¹ Department of Medicine, University of Washington

11 ² Department of Global Health, University of Washington

12 ³ VA Puget Sound Health Care System

13 ⁴ Department of Biostatistics, University of Washington

14 ⁵ Kenya Medical Research Institute, Nairobi, Kenya

15 ⁶ Infectious Diseases Institute, Makerere University, Kampala, Uganda

16 ⁷ Department of Pediatrics, University of Washington

17 ⁸ Gilead Sciences, Foster City

18 ⁹ Department of Epidemiology, University of Washington

19
20 **Corresponding author:** Javeed A. Shah, jashah@uw.edu; 206-543-8728

21
22 **Author Contributions:** AS: contributed to the design, data acquisition, analysis, and manuscript
23 preparation. JE: data analysis, manuscript preparation, sample collection and transport, TL:
24 statistical analysis, software, BR: data analysis, statistical support, manuscript editing; SH/HH:
25 sample transport, sample storage, database management, NM/AM: sample collection/storage,
26 participant enrollment, CC/JB: cohort enrollment, funding, sample storage, manuscript editing,
27 JL: cohort enrollment, sample storage, funding, manuscript editing, GJS: experimental design,
28 data analysis, funding, manuscript editing, SL: experimental design, data analysis, grant
29 funding, manuscript preparation and editing; JAS: experimental design, data analysis, grant
30 funding, manuscript preparation and editing.

31
32 **Grant Support:** NICHD R21-HD098746, NIAID K23-AI120793, R01-AI136921,
33 Bill & Melinda Gates Foundation 26469, 41185, and 47674

34
35 **Short Title:** Pregnancy and Mtb T cell responses

36
37 **Descriptor:** 11.4 Mycobacterial Disease: Host Defenses

38
39 **Total Word Count:** 3534

40
41 This title has an online data supplement which is accessible from this issue's table of content
42 online at www.atsjournals.org.

44 **Abstract**

45 Rationale: Pregnancy is a risk factor for progression from latent tuberculosis infection (LTBI) to
46 symptomatic tuberculosis (TB). However, how dynamic immunologic changes in pregnancy
47 influence immune responses to *M. tuberculosis* (Mtb) is unknown.

48 Objectives: We performed a detailed characterization of Mtb-specific T cell responses of women
49 at high risk for Mtb infection, leveraging a biorepository of longitudinally samples collected
50 before, during, and after pregnancy in high HIV/TB burden settings.

51 Methods: We used specimens collected from women who became pregnant while enrolled in a
52 randomized controlled trial of pre-exposure prophylaxis for HIV prevention. We measured Mtb-
53 specific cytokines, CCR7 and CD45RA memory markers, and overall CD4+ and CD8+ T cell
54 activation from 49 women using COMPASS, a Bayesian statistical method for evaluating overall
55 antigen-specific T cell responses measured by flow cytometry.

56 Measurements and Main Results: 22 LTBI+ women, defined by flow cytometry, demonstrated
57 significantly diminished Mtb-specific CD4+ cytokine responses in the third trimester (COMPASS
58 score (PFS) 0.07) compared before (PFS 0.15), during (PFS 0.13 and 0.16), and after
59 pregnancy (PFS 0.14; $p = 0.0084$, Kruskal-Wallis test). Paradoxically, Mtb-specific CD8+
60 cytokine responses and nonspecifically activated CD38+HLA-DR+CD4+ T cells increased
61 during late pregnancy. Nonspecific T cell activation, a previously validated biomarker for
62 progression from LTBI to TB disease, was increased in LTBI+ women postpartum, compared
63 with LTBI- women.

64 Conclusions: Pregnancy-related functional T cell changes were most pronounced during late
65 pregnancy. Mtb-specific T cell changes during pregnancy and postpartum, increases in immune
66 activation may contribute to increased risk for TB progression in the postpartum period.

67 Abstract Word Count: 245

68 Keywords: *M. tuberculosis*, pregnancy, T cells, T cell memory, T cell activation

69 **Introduction**

70 Tuberculosis (TB) disease in pregnancy and postpartum is associated with poor
71 maternal and infant outcomes (1, 2). Recent large cohort studies demonstrate that pregnancy is
72 associated with increased rates of tuberculosis disease (TB) up to six months postpartum (3, 4).
73 However, the immune mechanisms underpinning this observation are not clear. Successful
74 pregnancy requires dynamic alteration of the local immune environment (5-7). These
75 adaptations to fetal development are accompanied by cell-specific systemic immune alterations
76 (8). Pathogen-specific responses may be influenced by these systemic immune changes, which
77 can alter disease risk (9-11). Understanding pathogen-specific changes to the immune
78 response during pregnancy may improve efforts to prevent and control disease.

79
80 T cell responses are a critical aspect of Mtb host defense. Multiple lines of evidence,
81 including studies in mouse and nonhuman primate studies of CD4+ T cell knockout or depletion,
82 human genetic studies, and observational studies during HIV infection demonstrate that CD4+ T
83 cells are essential for Mtb control (12-16). Prior data suggests that IFN γ responses in CD4+ T
84 cells are essential for Mtb protection (17). The frequency of CD4+ T cells simultaneously
85 producing IL-2, TNF, and IFN γ (e.g., that are polyfunctional) is correlated with Mtb protection
86 (18). Other T cell phenotypes, such as central memory cells (Tcm) and CD8+ T cells, may
87 contribute to Mtb host defense (19-22). Conversely, increased total numbers of nonspecifically
88 activated HLA-DR+CD4+ T cells are a correlate of TB progression (23, 24). Since studies of
89 pregnancy commonly begin enrollment during the first or second trimester of pregnancy, they
90 are often unable to capture immune variation prior to and earlier in pregnancy. We leveraged a
91 unique biorepository of samples and data collected longitudinally before, during, and after
92 pregnancy from women in sub-Saharan Africa enrolled in a randomized controlled trial of pre-

93 exposure prophylaxis for HIV prevention to evaluate the effects of various stages of pregnancy
94 on Mtb-specific T cell responses.

95

96 **Methods**

97 *Study Population*

98 The protocol for this study was approved by the University of Washington Human Subjects
99 Review Committee and ethics review committee at each study site. All participants provided
100 written informed consent in English or their native language. The Partners PrEP Study was a
101 randomized clinical trial of antiretroviral pre-exposure prophylaxis (PrEP) in HIV serodiscordant
102 couples (25). 4758 total participants were enrolled from 9 sites in Kenya and Uganda between
103 2007 and 2012. Partners with HIV and CD4 cell count ≥ 250 , without history of AIDS-defining
104 diagnosis or current use of antiretroviral therapy (ART) were eligible. Participants without HIV
105 underwent monthly HIV testing from the parent trial and had urine pregnancy testing at
106 enrollment and monthly thereafter; women living with HIV (WLHIV) had urine collected quarterly.
107 WLHIV not already on ART who became pregnant were referred for prevention of maternal to
108 child transmission services. Participants were eligible for this analysis if they had at least two
109 samples available within 6 months prior to and during incident pregnancy. If available, additional
110 samples were tested from within 6 months postpartum. (**Figure 1A**). For participants with only
111 two timepoints available (before and during pregnancy), paired testing was done only on
112 participants with pregnancy samples from ≥ 20 weeks gestation after interim evaluation of data
113 from participants with three time points samples. WLHIV received antiretrovirals for prevention
114 of maternal to child transmission of HIV, but not for treatment based on the guidelines at the
115 time.

116

117 *Statistical Analysis*

118 We used the R package COMPASS to analyze the overall cytokine response of CD4+ and
119 CD8+ T cells and to determine cytokine-producing subsets. COMPASS uses a Bayesian
120 hierarchical framework to model all observed cell subsets and select those most likely to have
121 antigen-specific responses (26, 27). COMPASS provided a functional score (FS), which is the
122 proportion of antigen specific subsets detected among all possible ones, and polyfunctional
123 score (PFS), which is similar, but weighs the different subsets to favor subsets with higher
124 degrees of functionality. Our primary outcome of interest was the COMPASS PFS from CD4+
125 and CD8+ T cells of LTBI+ women with preexisting T cell responses against Mtb, restimulated
126 with pooled peptides from the Mtb-specific antigens ESAT-6 and CFP10. Differences in median
127 values were compared among timepoints of interest using Kruskal-Wallis tests as the primary
128 analysis, followed by Dunn's test to compare individual groups. Samples from women with and
129 without HIV were measured together except where indicated.

130

131 **Results**

132 *Cohort characteristics and timing of sample collection*

133 We identified 70 participants with incident pregnancy. 49 of these met criteria for this
134 study, with paired samples collected during pregnancy and another, collected less than 6
135 months prior to the pregnancy. 17 participants had samples collected from 3 timepoints (pre-,
136 during-, and post-pregnancy). 32 participants had samples collected before and during
137 pregnancy (**Figure 1A**). A total of 117 samples with evaluable results were analyzed; 48 pre-
138 pregnancy (median 18.7 weeks [IQR 12.4-22.2]), 47 during pregnancy, (median 26.9 weeks
139 gestation [IQR 12.7-30.9]); 22 post-partum (median 23.1 weeks [IQR 18.4-39.6]). The median
140 age of study participants was 26.4 years (IQR 23.2-31.1); 36.7% (18/49) were WLHIV with
141 median CD4 766 cells/mm³ [IQR 507-1070]) (**Table 1**).

142

143 *Identification of LTBI+ participants using flow cytometry*

144 We identified individuals with LTBI using their first evaluable sample using a flow-based
145 assay as TST or IGRA were not performed during the original trial. We defined individuals as
146 LTBI+ if their proportion of the frequency of IFN γ +CD4+ T cells doubled after ESAT-6 and CFP-
147 10 pooled peptide stimulation compared to DMSO. This measurement correlates well with
148 commercial IGRA tests (28-31). 22/49 (45%) individuals were LTBI+ by this measure (**Figure**
149 **1B**). We found that increasing the threshold for positivity to three-fold above background
150 reduced the proportion of LTBI+ individuals slightly, from 22 (44%) to 19 (41%). These
151 observations are similar in frequency to other studies of women of childbearing age in regions
152 with high Mtb burden (32). We used the initially identified more inclusive cutoff to ensure we
153 identified all individuals with pre-existing immune responses to Mtb. We identified three
154 individuals who were LTBI- at baseline but LTBI+ by their pregnancy visit. In these situations,
155 we included these individuals as LTBI+ from their first positive result onward.

156

157 *CD4+ and CD8+ T cell frequency is consistent before, during, and after pregnancy*

158 Our primary study objective was to identify the overall changes to the T cell response
159 using samples collected before, during, and after pregnancy among LTBI+ women. We first
160 identified the frequency of CD4+ and CD8+ T cells from samples collected before, during, and
161 after pregnancy (gating shown in **Figure S1A**). The frequency of CD4+ and CD8+ T cells was
162 similar over these time points (**Figure 1B-C**). In WLHIV, the frequency of CD4+ T cells was
163 lower than in women without HIV, irrespective of pregnancy status (**Figure S1B**) and CD8+ T
164 cell frequency was increased (**Figure S1C**). COMPASS FS and PFS of CD4+ T cells from all
165 samples strongly correlated with our LTBI measurements (**Figure 1E-F**).

166

167 *Mtb-specific CD4+ T cells polyfunctional responses decreased during the third trimester of*
168 *pregnancy*

169 Mtb induces a polyfunctional T cell response that may act independently of IFN γ , and
170 these cells are critical for Mtb control (33). In Mtb-specific CD4⁺ T cells, PFS was significantly
171 different before, during, and after pregnancy (**Figure 2A**, gating in Figure S2; $p = 0.0084$,
172 Kruskal-Wallis test). PFS was significantly decreased in the third trimester compared with pre-
173 pregnancy ($p = 0.0005$), second trimester ($p = 0.0034$) and post-pregnancy ($p < 0.017$), but not
174 during the first trimester ($p = 0.099$; **Figure 2A**). FS results were similar to PFS (**Figure 2B**). We
175 detected fewer Mtb-specific cytokine-producing subsets during third trimester, and very few
176 subsets producing multiple cytokines simultaneously (COMPASS heatmaps shown in **Figure**
177 **S3A**). We noted diminished single cytokine responses during the third trimester in IL-2+CD4⁺
178 cells compared with the second trimester (**Figure S3B**; $p = 0.026$) which trended lower
179 compared with pre-pregnancy ($p = 0.13$), first trimester ($p = 0.12$) and post-pregnancy ($p =$
180 0.09). CD4⁺TNF⁺ or CD4⁺IFN γ ⁺ responses were similar across pregnancy (**Figure S3C-D**).
181 Therefore, using COMPASS, we were able to detect changes to Mtb-specific T cell responses
182 that may be clinically important but not immediately detectable by analyzing single cytokines
183 separately.

184

185 *CD4⁺ T cell responsiveness to a mitogen is altered during the third trimester*

186 Clinical laboratory tests for LTBI include mitogen controls to assess overall T cell
187 reactivity; impacts to mitogen induced CD4⁺ and CD8⁺ T cell responses during pregnancy
188 directly alter LTBI diagnostic test performance (34). We compared T cell responses after
189 stimulation with phorbol 12-myristate 13-acetate and ionomycin (PMA/ionomycin) over
190 pregnancy in all study participants. We evaluated these T cell responses using traditional flow
191 cytometry analysis, not COMPASS, as COMPASS is designed to detect antigen specific
192 responses observed at low frequency. The frequency of IL2+CD4⁺ T cells responding to
193 PMA/ionomycin were significantly changed over the duration of pregnancy (**Figure 3A**, p

194 <0.0001, Kruskal-Wallis test). IL-2+CD4+ responses in the third trimester were increased
195 compared to pre-pregnancy ($p = 0.022$), first trimester ($p = 0.0006$) and post-pregnancy ($p <$
196 0.0001). TNF+CD4+ responses were also significantly increased during the third trimester
197 compared to first trimester ($p = 0.0073$) and post-pregnancy ($p = 0.0002$; **Figure 3B**, $p = 0.0011$
198 overall). IFN γ +CD4+ cells decreased across pregnancy ($p = 0.0036$). The third trimester
199 response was significantly diminished compared to pre-pregnancy ($p = 0.016$), first trimester (p
200 $= 0.026$), second trimester ($p = 0.049$), and post-pregnancy (**Figure 3C**; $p = 0.0001$). IL-2+,
201 TNF+, and IFN γ + CD4+ T cell frequencies were each significantly different before and after
202 pregnancy ($p = 0.006$, $p = 0.008$, and $p = 0.04$, respectively), suggesting that systemic immune
203 alterations of pregnancy begin during the first trimester and persist for weeks to months after
204 birth. These data demonstrate distinct patterns of CD4+ T cell activation across pregnancy as
205 compared to Mtb-specific T cells.

206

207 *Mtb-specific CD8+ T cells increase in activity during the second and third trimester of pregnancy*

208 CD8+ T cells contribute to Mtb host defense and are measured in LTBI diagnostic tests
209 (35, 36), but little is known about how pregnancy impacts Mtb-specific CD8+ T cell responses.
210 We found low but detectable Mtb-specific CD8+ T cell cytokine responses in most samples from
211 LTBI+ participants (**Figure S2**, gating strategy). The PFS and FS in CD8+ T cells changed
212 significantly over the course of pregnancy (**Figure 4A-B**; $p = 0.0033$ and $p = 0.038$ respectively,
213 Kruskal-Wallis test). Median PFS in CD8+ T cells was nearly undetectable before pregnancy
214 and significantly increased in the second trimester compared with pre-pregnancy ($p = 0.015$),
215 the first trimester ($p = 0.023$), and post-pregnancy ($p = 0.034$). A similar trend was observed in
216 FS. The complexity of the CD8+ T cell response increased during the second and third
217 trimester, and we detected subsets producing multiple cytokines simultaneously (**Figure S4A**).
218 We were unable to detect shifts in IL-2, TNF, and IFN γ + CD8+ T cell responses when evaluated

219 singly, but we found a trend toward increased responses in each cytokine during the second
220 and third trimester (**Figure S4B-D**). Taken together, Mtb-specific CD8+ T cell responses
221 increased during the second and third trimester, while Mtb-specific CD4+ T cell responses
222 diminished during the same period.

223

224 *Mitogen-induced TNF+ CD8+ T cell responses increase during pregnancy*

225 We measured the changes in PMA/ionomycin-stimulated CD8+ T cell responses over
226 the course of pregnancy in all participants. IL-2+CD8+ responses were unchanged by
227 pregnancy trimester (**Figure 5D**; $p = 0.14$, Kruskal-Wallis test). TNF+CD8+ T cell frequency
228 changed over the course of pregnancy (**Figure 5E**; $p = 0.0084$) and increased in the third
229 trimester compared with the first trimester ($p = 0.015$) and post-pregnancy ($p = 0.0018$).
230 IFN γ +CD8+ T cell frequencies were similar across pregnancy (**Figure 5F**). These responses
231 were distinct from the changes observed in Mtb-specific CD8+ T cells, where multiple subsets
232 increased in frequency during the second and third trimester.

233

234 *Mtb-specific effector memory T cell populations diminish during the third trimester*

235 T cells display cell surface markers CD45RA and CCR7 as markers of T cell memory
236 phenotype (37). Naïve (CCR7+CD45RA+), central memory (Tcm; CCR7+CD45RA-), and
237 effector memory (Tem; CCR7-CD45RA-) T cells display distinct functional profiles and tissue
238 homing sites, and Tcm are important for Mtb control (38-40). Naïve and Tcm produce little IFN γ ,
239 but Tem does not provide extended protection against disease. The frequency of total CD4+
240 and CD8+ T cells expressing CD45RA and CCR7 did not change over pregnancy (**Figure S5A-**
241 **C**). We evaluated CD45RA and CCR7 expression in Mtb-specific CD4+ T cells, which were
242 ESAT-6 and CFP-10 peptide incubated, cytokine-producing, CD4+ T cells from LTBI+
243 individuals. The proportion of Mtb-specific naïve and Tcm CD4+ T cells remained stable (**Figure**

244 **6A-B**), but we observed reduced Tem frequency during the third trimester (**Figure 6C**, $p =$
245 0.037 ; Kruskal-Wallis test) compared to pre-pregnancy ($p = 0.049$), first trimester ($p = 0.005$),
246 second trimester ($p = 0.014$), and postpartum ($p = 0.031$). Viewed proportionally, naïve CD4+
247 cells increased while Tem decreased during the third trimester of pregnancy compared to the
248 first trimester, second trimester, and postpartum, without substantial changes to Tcm frequency
249 (**Figure 6D**). We did not detect adequate Mtb-specific CD8+ T cells to evaluate T cell
250 phenotypes in this population. In sum, Tem and IFN γ +CD4+ cells were reduced during the third
251 trimester, but without increases in the Tcm population, which is important for Mtb host defense
252 and may predict worsened Mtb control.

253

254 *Nonspecific T cell activation increases during pregnancy*

255 Increased nonspecific CD4+ T cell activation is a correlate of risk for developing Mtb
256 disease (41, 42). We measured the frequency of HLA-DR+CD38+ CD4+ and CD8+ T cells
257 across pregnancy, using “flow minus one” controls (**Figure S6A**). The frequency of HLA-
258 DR+CD38+ CD4+ T cells significantly changed over pregnancy (**Figure 7A**; $p < 0.0001$,
259 Kruskal-Wallis test), highest in the third trimester compared to pre-pregnancy ($p = 0.0068$), first
260 trimester ($p < 0.0001$), second trimester ($p = 0.007$), or postpartum (**Figure 7A**; $p < 0.0001$).
261 HLA-DR+CD38+ CD8+ T cell frequency also significantly changed similarly to CD4+ T cells
262 (**Figure 7B**; $p < 0.0001$, Kruskal-Wallis test). In both CD4+ and CD8+ T cells, activation markers
263 decreased from pre-pregnancy to the first trimester, and WLHIV demonstrated the greatest T
264 cell activation throughout pregnancy. Therefore, T cell activation decreases at the outset of
265 pregnancy, then increases over time until delivery.

266 We leveraged the observation that CD4+ T cell activation is a biomarker for TB risk to
267 evaluate if the immune changes of pregnancy might increase the risk for TB progression from
268 asymptomatic to symptomatic disease. We hypothesized that selective increases in nonspecific
269 T cell activation would be present in LTBI+ women after pregnancy due to their increased risk

270 for postpartum Mtb progression but not for LTBI- women. Pre-pregnancy, the proportion of
271 HLADR+CD38+CD4+ T cells was equivalent between LTBI- and LTBI+ individuals (**Figure 7C**).
272 Postpartum, LTBI+ individuals demonstrated significantly higher HLA-DR+CD38+ CD4+ T cells
273 as compared to LTBI- individuals (**Figure 7D**; $p = 0.0026$, Mann-Whitney test). Immune
274 changes of pregnancy in LTBI+ individuals may substantially contribute to overall T cell
275 activation in the postpartum period and predict increased risk for TB progression.

276

277 **Discussion**

278 In this study, we performed a comprehensive analysis of pregnancy stage on Mtb-
279 specific T cell phenotypes in sub-Saharan African women including women living with HIV.
280 These data are, to our knowledge, the first longitudinal assessment of systemic T cell responses
281 to Mtb in pregnancy that includes samples collected prior to pregnancy. Taken in sum, we found
282 that late pregnancy is associated with multiple changes to Mtb-specific T cell function: 1) overall
283 Mtb-specific CD4+ T cell responses diminished and simplified; 2) Mtb-specific CD4+ Tem, which
284 are cells that strongly produce IFN γ , decreased (37); 3) Mtb-specific CD8+ T cell responses
285 increased, and 4) nonspecific T cell activation increased. (**Figure 8**). Nonspecific T cell
286 activation increased in LTBI+ individuals compared to LTBI- individuals postpartum, despite
287 being equivalent pre-pregnancy. Increased nonspecific T cell activation, a correlate of risk for
288 Mtb disease in LTBI+ individuals, supports the observation that TB risk increases in the early
289 postpartum period (41). Together, late pregnancy induces complex changes in the known T cell
290 response to Mtb that have been associated with TB progression in other populations, and we
291 found that LTBI+ women develop increased correlates of risk for TB in the immediate
292 postpartum period.

293

294 We observed distinct changes between Mtb-specific and more generalized mitogen
295 (PMA/ionomycin)-induced T cell cytokine responses. These results have direct implications

296 toward the performance of LTBI diagnostics in pregnant women. Mtb-specific CD4+ T cell
297 responses decreased during the third trimester but increased in the second trimester, and Mtb-
298 specific CD8+ T cell responses were low but increased during the second and third trimester.
299 By contrast, overall mitogen responses in CD4+ T cells, especially IL-2 responses, increased
300 during late pregnancy. In other cohorts, discordance between the two commonest LTBI tests,
301 TST and IGRA, has been noted especially among women in the late second and early third
302 trimester, which may be partly due to the changes in the immune responses of pregnancy (34,
303 43). Part of the difference may be due to the absence of mitogen testing in most TSTs.
304 Understanding this discordance in pregnancy may have implications for TB progression. Among
305 those with positive IGRA but negative TST tests, Mtb-specific IL-2 responses associated with
306 postpartum TB progression from asymptomatic infection to symptomatic disease (44). In
307 combination, discordance between Mtb-specific and nonspecific immune responses may
308 contribute to increased false-negative LTBI testing during the third trimester and may contribute
309 to Mtb progression.

310

311 Conversely, we found that Mtb-specific CD8+ T cell responses increased during late
312 pregnancy when CD4+ T cell responses were diminished. The role of CD8+ T cells in TB
313 pathogenesis is uncertain. In children, Mtb-specific CD8+ T cell frequencies are correlated with
314 Mtb disease (45). In animals, CD8+ T cell responses correlate strongly with Mtb bacterial
315 burden in the lung (46, 47). CD8+ T cells recognize antigens presented on major
316 histocompatibility complex I, which presents intracellular antigens. CD8+ T cells preferentially
317 recognize antigen-presenting cells with an increased bacterial burden (48). During active
318 intracellular infection, these responses may increase proportionally. It is unclear if some of these
319 responses reflect emerging TB disease or if there are general postpartum factors that enhance
320 CD8+ responses. These data suggest that CD8+ T cell responses may increase to compensate

321 for diminished CD4+ T cell responses but may be unable to fully reproduce CD4+ T cell immune
322 control.

323

324 The strengths of this study include its longitudinal nature, including samples obtained
325 before, during, and after pregnancy. Most studies of the effects of pregnancy enroll women
326 during pregnancy and often focus on the second and third trimester, which do not capture pre-
327 pregnancy and first trimester periods. Several T cell phenotypes change significantly between
328 pre-pregnancy and the first trimester, and other phenotypes differed between pre-pregnancy
329 and postpartum. Local inflammation is critical for embryonic implantation, which suggests that
330 both local and systemic immune changes begin immediately and are prolonged post-partum
331 (49, 50). Another strength of this study was the use of COMPASS. COMPASS analysis
332 revealed two findings that were not observable using standard data analysis techniques. This
333 sensitive analysis permitted us to observe the diminished complexity of the Mtb-specific CD4+ T
334 cell response during the third trimester and increases in overall CD8+ activity. Taken together,
335 no single cytokine response accounted for the changes to the Mtb-specific T cell response,
336 suggesting broad changes in the functional capacity of T cells responding to antigen during the
337 third trimester.

338

339 Weaknesses of this study include the lack of TB disease outcomes data. This study
340 used repository samples from a trial not originally designed to evaluate TB. However, we
341 performed detailed immune characterization of the changes to the Mtb-specific immune
342 response across pregnancy. Importantly, LTBI+ women had increased T cell activation
343 postpartum, when compared with LTBI- women, which is a validated biomarker of TB disease
344 progression in other cohorts (23). IGRA or TST was not performed in the parent study, which
345 prevents correlation with clinically validated LTBI testing. However, the method we used in this
346 study to identify LTBI+ participants is a well-accepted alternate approach that correlates with

347 LTBI diagnosis (30, 31). Generally, flow-based testing is more sensitive to detect prior exposure
348 to Mtb antigens than IGRA, so this approach permits us to evaluate a broader range of
349 individual immune responses. Errors introduced by the inclusion of individuals without
350 preexisting Mtb exposures are likely to reduce the sensitivity of this analysis to detect changes.
351 We performed sensitivity analyses by raising the threshold for LTBI+ identification, but this did
352 not substantially change the number of participants considered to have LTBI. Due to the limited
353 sample size of this study, we did not perform formal analysis to investigate the impact of HIV on
354 immune responses during pregnancy. Although HIV status was associated with reduced CD4+
355 T cell count and increased T cell activation, we found immune changes of pregnancy were
356 generally independent of HIV status, though direct comparisons were limited due to small
357 sample size.

358
359 TB is the third leading cause of death among women of child-bearing age in high burden
360 areas and is associated with morbidity and mortality in pregnant women and their children,
361 especially among those affected by HIV (1, 43). Our study provides evidence that systemic
362 changes in the T cell response during the third trimester may contribute to increased risk for TB
363 progression. T cell cytokine responses are reduced and simplified, T cell memory phenotypes
364 skewed toward naïve phenotypes, and nonspecific activation is enhanced, which all are
365 independently associated with TB risk. Recent data suggest that isoniazid preventative therapy
366 is associated with adverse pregnancy outcomes, with a signal that this may occur more often if
367 initiated early in pregnancy (51). As such, late pregnancy, which is associated with key
368 immunologic changes for TB progression, may be an advantageous time to target for shorter
369 course regimens. Understanding host factors that place pregnant mothers at risk for TB may
370 provide insight into optimal public health strategies for TB control in this high-risk population.

371

372 **Acknowledgements**

373 The authors would like to thank the study participants and their families. We would like to
374 acknowledge the support of Harald Haugen on database management of clinical samples. We
375 would also like to acknowledge the clinical teams who obtained informed consent and collected
376 samples for this biorepository. We would also like to thank Chetan Seshadri for helpful technical
377 conversations.

378 **Figure Legends**

379 **Figure 1. Baseline Immune Characteristics Are Stable Across Pregnancy.**

380 A) Flowchart of stored sample selection of participants with incidental pregnancies in the
381 Partners PrEP study.

382 B) Proportion of CD4+ T cells of all CD3+ cells, by pregnancy, trimester, and HIV status. Here
383 and throughout, Samples indicated with *black circles* are from HIV- donors, while *gold triangles*
384 are from WLHIV here and throughout this study.

385 C) Proportion of CD8+ T cells, stratified by pregnancy, trimester, and HIV status.

386 Pre-pregnancy sample N = 49; 1st trimester N = 9, 2nd trimester N = 14; 3rd trimester N = 24;
387 postpartum N = 22. *Black circles* indicate HIV- study participants, while *gold triangles* indicate
388 WLHIV here and throughout this paper. Bars indicate median values. Statistical difference
389 between CD4 and CD8+ T cells was measured by Kruskal-Wallis test with sub-analysis
390 comparing column medians.

391 D) Fold change of the proportion of CD4+ T cells expressing IFN γ after incubation with ESAT-6
392 and CFP-10 pooled peptides, compared to vehicle control.

393 E) COMPASS functional score (FS), stratified by LTBI status.

394 F) COMPASS polyfunctional score (PFS), stratified by LTBI status.

395

396 **Figure 2. Mtb-specific CD4+ T cell responses are diminished during the third trimester of**
397 **pregnancy.**

398 A) Polyfunctional scores (PFS) generated from COMPASS analysis, stratified by pregnancy
399 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.
400 Bars indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-
401 to-column comparisons are made with Dunn's test.

402 B) Functional scores (FS) generated from COMPASS analysis, stratified by pregnancy
403 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.

404 Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, Kruskal-Wallis test. Column-
405 to-column comparisons are made with Dunn's test.

406

407 **Figure 3. PMA/ionomycin-stimulated CD4+ T cell cytokine responses are dynamic across**
408 **pregnancy.**

409 A-C) Proportion of A) IL-2+CD4+, B) TNF+CD4+, or C) IFN γ +CD4+ T cells, stratified by
410 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a
411 WLHIV. Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, GEE with estimating
412 equation, connected by *overhead bar*.

413 D-F) Proportion of D) IL-2+CD4+, E) TNF+CD4+, or F) IFN γ +CD4+ T cells, stratified by
414 pregnancy trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate
415 an HIV+ study participant. Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$,
416 Overall significant by Kruskal-Wallis test demonstrated with top, *thick line without overhangs*.
417 Column-to-column comparisons are made with Dunn's test and shown with *thinner bars with*
418 *overhangs*.

419

420 **Figure 4. Mtb-specific CD8+ T cell polyfunctionality increases during the second**
421 **trimester of pregnancy.**

422 A) Polyfunctional scores (PFS) generated from COMPASS analysis, stratified by pregnancy
423 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.
424 Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, Kruskal-Wallis test. Column-
425 to-column comparisons are made with Dunn's test. *Black dots* indicate an HIV- study
426 participant, while *gold triangles* indicate a sample from WLHIV study participant.

427 B) Functional scores (FS) generated from COMPASS analysis, stratified by pregnancy
428 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.

429 Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, Kruskal-Wallis test. Column-
430 to-column comparisons are made with Dunn's test.

431
432 **Figure 5. Cytokine responses in PMA/ionomycin-stimulated CD8+ T cells are stable**
433 **during pregnancy.**

434 A-C) Proportion of A) IL-2+CD8+, B) TNF+CD8+, or C) IFN γ +CD8+ T cells, stratified by
435 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate an
436 HIV+ study participant. Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, GEE
437 with estimating equation, connected by *overhead bar*.

438 D-F) Proportion of D) IL-2+CD8+, E) TNF+CD8+, or F) IFN γ +CD8+ T cells, stratified by
439 pregnancy trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate
440 an HIV+ study participant. Bars indicate median values. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$,
441 Kruskal-Wallis test. Column-to-column comparisons are made with Dunn's test.

442
443 **Figure 6. Proportions of Mtb-specific naïve CD4+ T cells increase and effector memory T**
444 **cells decrease during the third trimester of pregnancy.**

445 A-C) Overall proportion of A) naïve (CCR7+CD45RA+), B) central memory (T_{CM}; CCR7+CD45RA-), and C) effector memory (T_{EM}; CCR7-CD45RA-) among all cytokine-
446 producing CD4+ T cells after re-stimulation with ESAT-6 and CFP-10 antigens, stratified by
447 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a
448 sample from WLHIV study participant. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, Kruskal-Wallis test.
449 Column-to-column comparisons are made with Dunn's test.

450
451 D) Pie chart of Boolean-gated T helper memory phenotype frequencies, comparing the third
452 trimester with other timepoints, connected by *overhead bar*. *Blue arc* indicates CCR7+ cells, *red*
453 *arc* indicates CD45RA+ cells. *Red pie slice*: Naïve CD4+ T cells (Naïve); *blue pie slice*: effector

454 memory CD4+ T cells (Tem); *gray* slice: central memory T cell (Tcm); *white* slice: TEMRA cell
455 (TEMRA). * P < 0.05, ** P < 0.01, *** P < 0.001, permutation test of 10000 iterations.

456

457 **Figure 7. Nonspecific T cell activation increases during pregnancy and LTBI+ women**
458 **demonstrate increased T cell activation postpartum**

459 A) Proportion of HLA-DR+CD38+ CD4+ T cells, stratified by pregnancy status.

460 B) Proportion of HLA-DR+CD38+ CD8+ T cells, stratified by pregnancy status.

461 C) Proportion of HLA-DR+CD38+ CD4+ T cells from samples collected pre-pregnancy, stratified
462 by LTBI status of the participant.

463 D) Proportion of HLA-DR+CD38+ CD4+ T cells from samples collected postpartum, stratified by
464 LTBI status of the participant. *Black dots* indicate an HIV- study participant, while *gold triangles*
465 indicate sample from WLHIV. Thick bars correspond to overall changes (Kruskal-Wallis test).
466 *Bars with overhangs* indicate analysis of differences between columns (Dunn's test). Bars
467 indicate median values. * P < 0.05, ** P < 0.01, *** P < 0.001, Kruskal-Wallis test. Column-to-
468 column comparisons are made with Dunn's test in multiple group comparisons or Mann-Whitney
469 U-test for tests between two groups.

470

471 **Figure 8. Summary of overall Mtb-specific T cell responses during differing stages of**
472 **pregnancy.** We observed distinct changes in Mtb-specific T cell responses as compared to
473 mitogen-stimulated T cells. Arrows indicate the overall frequency of the responses measured. A
474 downward arrow followed by an upward arrow indicates diminished IL-2/TNF responses with
475 simultaneous increases in IFN γ + cell frequency, and an upward arrow followed by a downward
476 arrow indicates increases in IL-2/TNF+ T cell frequency with decreases in IFN γ + responses.

References

- 477
478
479 1. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women:
480 epidemiology, management, and research gaps. *Clin Infect Dis* 2012; 55: 1532-
481 1549.
- 482 2. Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered
483 questions for pregnant and postpartum women living with HIV: the need for
484 improved evidence. *J Int AIDS Soc* 2020; 23: e25481.
- 485 3. Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active
486 tuberculosis during pregnancy and postpartum: a register-based cohort study in
487 Sweden. *Eur Respir J* 2020; 55.
- 488 4. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy:
489 a national, primary care-based cohort and self-controlled case series study. *Am J*
490 *Respir Crit Care Med* 2012; 185: 779-784.
- 491 5. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of
492 pregnancy. *Nat Rev Immunol* 2017; 17: 469-482.
- 493 6. Erlebacher A. Immunology of the Maternal-Fetal Interface. *Annual Review of*
494 *Immunology* 2013; 31: 387-411.
- 495 7. Shah NM, Herasimtschuk AA, Boasso A, Benlahrech A, Fuchs D, Imami N, Johnson
496 MR. Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy
497 Are Indicative of a Shift from Immune Tolerance to Immune Activation. *Front*
498 *Immunol* 2017; 8: 1138.
- 499 8. Aghaeepour N, Ganio EA, McIlwain D, Tsai AS, Tingle M, Van Gassen S, Gaudilliere
500 DK, Baca Q, McNeil L, Okada R, Ghaemi MS, Furman D, Wong RJ, Winn VD,

- 501 Druzin ML, El-Sayed YY, Quaintance C, Gibbs R, Darmstadt GL, Shaw GM,
502 Stevenson DK, Tibshirani R, Nolan GP, Lewis DB, Angst MS, Gaudilliere B. An
503 immune clock of human pregnancy. *Sci Immunol* 2017; 2.
- 504 9. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and Infection. *New England Journal*
505 *of Medicine* 2014; 370: 2211-2218.
- 506 10. Racicot K, Mor G. Risks associated with viral infections during pregnancy. *J Clin*
507 *Invest* 2017; 127: 1591-1599.
- 508 11. Kay AW, Fukuyama J, Aziz N, Dekker CL, Mackey S, Swan GE, Davis MM, Holmes
509 S, Blish CA. Enhanced natural killer-cell and T-cell responses to influenza A virus
510 during pregnancy. *Proc Natl Acad Sci U S A* 2014; 111: 14506-14511.
- 511 12. Leveton C, Barnass S, Champion B, Lucas S, De Souza B, Nicol M, Banerjee D,
512 Rook G. T-cell-mediated protection of mice against virulent Mycobacterium
513 tuberculosis. *Infection and immunity* 1989; 57: 390-395.
- 514 13. Sakai S, Mayer-Barber KD, Barber DL. Defining features of protective CD4 T cell
515 responses to Mycobacterium tuberculosis. *Curr Opin Immunol* 2014; 29: 137-
516 142.
- 517 14. Müller I, Cobbold S, Waldmann H, Kaufmann S. Impaired resistance to
518 Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+
519 and Lyt-2+ T cells. *Infection and immunity* 1987; 55: 2037-2041.
- 520 15. Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, Flynn JL. CD4 T cell
521 depletion exacerbates acute Mycobacterium tuberculosis while reactivation of
522 latent infection is dependent on severity of tissue depletion in cynomolgus
523 macaques. *AIDS Res Hum Retroviruses* 2012; 28: 1693-1702.

- 524 16. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on
525 incidence of tuberculosis in South Africa: a cohort study. *The Lancet* 2002; 359:
526 2059-2064.
- 527 17. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL.
528 CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of Pulmonary
529 Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1
530 to Prevent Lethal Disease. *PLoS Pathog* 2016; 12: e1005667.
- 531 18. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ.
532 Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not
533 spleen, correlate with protection against Mycobacterium tuberculosis aerosol
534 challenge in mice. *The Journal of Immunology* 2008; 181: 4955-4964.
- 535 19. Lindenstrom T, Knudsen NP, Agger EM, Andersen P. Control of chronic
536 mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central
537 memory cells. *J Immunol* 2013; 190: 6311-6319.
- 538 20. Andersen P, Urdahl KB. TB vaccines; promoting rapid and durable protection in the
539 lung. *Curr Opin Immunol* 2015; 35: 55-62.
- 540 21. Grotzke JE, Lewinsohn DM. Role of CD8(+) T lymphocytes in control of
541 Mycobacterium tuberculosis infection. *Microbes and Infection* 2005; 7: 776-788.
- 542 22. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa
543 S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF,
544 Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA. CD8+
545 T cells provide an immunologic signature of tuberculosis in young children. *Am J*
546 *Resp Crit Care* 2012; 185: 206-212.

- 547 23. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M,
548 Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L,
549 Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,
550 Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H,
551 Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell
552 activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*
553 2016; 7: 11290.
- 554 24. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM,
555 Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and
556 monitor treatment response. *J Clin Invest* 2015; 125: 1827-1838.
- 557 25. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW,
558 Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH,
559 Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-
560 Joloba E, Twesigye R, Ngure K, Apaka C, Tamooch H, Gabona F, Mujugira A,
561 Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen
562 H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C,
563 Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C.
564 Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.
565 *New England Journal of Medicine* 2012; 367: 399-410.
- 566 26. Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M,
567 Hoal EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR. A
568 Functional TOLLIP Variant is Associated with BCG-Specific Immune Responses
569 and Tuberculosis. *Am J Respir Crit Care Med* 2017.

- 570 27. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H,
571 Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal
572 J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ,
573 Karasavvas N, Gilbert P, S CDR, McElrath MJ, Gottardo R. COMPASS identifies
574 T-cell subsets correlated with clinical outcomes. *Nat Biotechnol* 2015; 33: 610-
575 616.
- 576 28. Tesfa L, Koch FW, Pankow W, Volk HD, Kern F. Confirmation of Mycobacterium
577 tuberculosis infection by flow cytometry after ex vivo incubation of peripheral
578 blood T cells with an ESAT-6-derived peptide pool. *Cytometry Part B: Clinical*
579 *Cytometry: The Journal of the International Society for Analytical Cytology* 2004;
580 60: 47-53.
- 581 29. Papageorgiou CV, Anastasopoulos A, Ploussi M, Leventopoulos M, Karabela S,
582 Fotiadis K, Papavasileiou A, Vogiatzakis E, Ioakeimidis D, Gritzapis AD, Poulakis
583 N. Flow cytometry analysis of CD4+IFN-gamma+ T-cells for the diagnosis of
584 mycobacterium tuberculosis infection. *Cytometry B Clin Cytom* 2016; 90: 303-
585 311.
- 586 30. Lee J, Lee SY, Won DI, Cha SI, Park JY, Kim CH. Comparison of whole-blood
587 interferon-gamma assay and flow cytometry for the detection of tuberculosis
588 infection. *J Infect* 2013; 66: 338-345.
- 589 31. Sauzullo I, Scrivo R, Mengoni F, Ermocida A, Coppola M, Valesini G, Vullo V,
590 Mastroianni CM. Multi-functional flow cytometry analysis of CD4+ T cells as an
591 immune biomarker for latent tuberculosis status in patients treated with tumour
592 necrosis factor (TNF) antagonists. *Clin Exp Immunol* 2014; 176: 410-417.

- 593 32. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women:
594 Epidemiology, Management, and Research Gaps. *Clinical Infectious Diseases*
595 2012; 55: 1532-1549.
- 596 33. Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH,
597 McKittrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR,
598 Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G. IFN- γ -independent
599 immune markers of Mycobacterium tuberculosis exposure. *Nat Med* 2019; 25:
600 977-987.
- 601 34. LaCourse SM, Cranmer LM, Matemo D, Kinuthia J, Richardson BA, Horne DJ,
602 John-Stewart G. Effect of Pregnancy on Interferon Gamma Release Assay and
603 Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected
604 Women in a High Burden Setting. *J Acquir Immune Defic Syndr* 2017; 75: 128-
605 136.
- 606 35. Lin PL, Flynn JL. CD8 T cells and Mycobacterium tuberculosis infection. *Semin*
607 *Immunopathol* 2015; 37: 239-249.
- 608 36. Tsuyuzaki M, Igari H, Okada N, Suzuki K. Role of CD8 T-cell in immune response to
609 tuberculosis-specific antigen in QuantiFERON-TB Gold Plus. *J Infect Chemother*
610 2020; 26: 570-574.
- 611 37. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection:
612 implications for vaccine design. *Nat Rev Immunol*; 2008. p. 247-258.
- 613 38. Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory.
614 *Immunity* 2018; 48: 214-226.

- 615 39. Lindenstrøm T, Knudsen NPH, Agger EM, Andersen P. Control of chronic
616 Mycobacterium tuberculosis infection by CD4 KLRG1– IL-2–secreting central
617 memory cells. *The Journal of Immunology* 2013; 190: 6311-6319.
- 618 40. Vogelzang A, Perdomo C, Zedler U, Kuhlmann S, Hurwitz R, Gengenbacher M,
619 Kaufmann SH. Central memory CD4+ T cells are responsible for the recombinant
620 bacillus Calmette-Guerin Δ ureC:: hly vaccine's superior protection against
621 tuberculosis. *The Journal of infectious diseases* 2014; 210: 1928-1937.
- 622 41. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M,
623 Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L,
624 Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,
625 Darboe F, Penn-Nicholson A, Nemes E, Hatheril M, Hussey G, Mahomed H,
626 Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell
627 activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*
628 2016; 7: 11290.
- 629 42. Arenas-Hernandez M, Romero R, Xu Y, Panaitescu B, Garcia-Flores V, Miller D,
630 Ahn H, Done B, Hassan SS, Hsu CD, Tarca AL, Sanchez-Torres C, Gomez-
631 Lopez N. Effector and Activated T Cells Induce Preterm Labor and Birth That Is
632 Prevented by Treatment with Progesterone. *J Immunol* 2019; 202: 2585-2608.
- 633 43. Mathad JS, Bhosale R, Sangar V, Mave V, Gupte N, Kanade S, Nangude A,
634 Chopade K, Suryavanshi N, Deshpande P, Kulkarni V, Glesby MJ, Fitzgerald D,
635 Bharadwaj R, Sambarey P, Gupta A. Pregnancy differentially impacts
636 performance of latent tuberculosis diagnostics in a high-burden setting. *PLoS*
637 *One* 2014; 9: e92308.

- 638 44. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N,
639 Gupte N, Joshi S, Chandanwale A, Dupnik KM, Kulkarni V, Deshpande P,
640 Fitzgerald DW, Gupta A. Quantitative IFN-gamma and IL-2 Response Associated
641 with Latent Tuberculosis Test Discordance in HIV-infected Pregnant Women. *Am*
642 *J Respir Crit Care Med* 2016; 193: 1421-1428.
- 643 45. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa
644 S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF,
645 Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA, Unit
646 TR. CD8+ T Cells Provide an Immunologic Signature of Tuberculosis in Young
647 Children. *Am J Resp Crit Care* 2012; 185: 206-212.
- 648 46. Lewinsohn DM, Tydeman IS, Frieder M, Grotzke JE, Lines RA, Ahmed S, Prongay
649 KD, Primack SL, Colgin LMA, Lewis AD, Lewinsohn DA. High resolution
650 radiographic and fine immunologic definition of TB disease progression in the
651 rhesus macaque. *Microbes and Infection* 2006; 8: 2587-2598.
- 652 47. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J. Induction of CD8 T Cells
653 against a Novel Epitope in TB10.4: Correlation with Mycobacterial Virulence and
654 the Presence of a Functional Region of Difference-1. *The Journal of Immunology*
655 2007; 179: 3973-3981.
- 656 48. Lewinsohn DA, Heinzl AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM.
657 Mycobacterium tuberculosis-specific CD8+ T Cells Preferentially Recognize
658 Heavily Infected Cells. *Am J Resp Crit Care* 2003; 168: 1346-1352.

- 659 49. Zenclussen AC, Hämmerling GJ. Cellular Regulation of the Uterine
660 Microenvironment That Enables Embryo Implantation. *Front Immunol* 2015; 6:
661 321.
- 662 50. Gnainsky Y, Granot I, Aldo P, Barash A, Or Y, Mor G, Dekel N. Biopsy-induced
663 inflammatory conditions improve endometrial receptivity: the mechanism of
664 action. *Reproduction* 2015; 149: 75-85.
- 665 51. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T,
666 Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A,
667 Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesselning A, Shin K,
668 Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A,
669 Team IPTBAS. Isoniazid Preventive Therapy in HIV-Infected Pregnant and
670 Postpartum Women. *New England Journal of Medicine* 2019; 381: 1333-1346.
671

672

Table 1. Baseline characteristics of participants and timing of samples with evaluable results

Characteristic	Overall	LTBI+*	LTBI-	RR (95% CI)	p
	Median (IQR) or n (%)	Median (IQR) or n (%)	Median (IQR) or n (%)		
Baseline	N=49**	N=19	N=30		
Age (years)	26.4 (23.2-31.3)	26.8 (23.2-31.1)	26.2 (22.7-31.5)	1.02 (0.94-1.10)	0.624
WLHIV	18 (36.7)	6 (31.6)	12 (40.0)	0.79 (0.36-1.74)	0.565
CD4 (cells/mm ³)	765.5 (507-1070)	868.5 (588-1272)	730.5 (476.5-1042)	1.00 (1.00-1.00)	0.258
Samples	N=117	N=48	N=69		
Pregnancy stage				1.10 (0.83-1.47)	0.496
Pre-pregnancy [^]	48 (41.0)	18 (37.5)	30 (43.5)		
Pregnancy	47 (40.2)	20 (41.7)	27 (39.1)	0.77 (0.52-1.14)	0.184
1 st trimester (0 to <14 weeks)	9 (19.2)	5 (25.0)	4 (14.8)		
2 nd trimester (14 to <28 weeks)	14 (29.8)	7 (35.0)	7 (25.9)		
3 rd trimester (≥28 weeks)	24 (51.1)	8 (40.0)	16 (59.3)		
Post-pregnancy ^{***}	22 (18.8)	10 (20.8)	12 (17.4)		
Timing of sample collection (weeks)					
Pre-pregnancy	-18.7 (-22.2 – -12.4)	-18.3 (-22.3 – -11.7)	-18.8 (-22.1 – -13.1)	1.00 (0.96-1.03)	0.836
During pregnancy	26.9 (12.7-30.9)	18.9 (11.7-28.1)	28.7 (22.4-32.0)	0.97 (0.94-1.00)	0.077
Post-pregnancy	23.1 (18.4-39.6)	19.5 (17.3-45.6)	30.5 (21.4-38.7)	1.00 (0.97-1.03)	0.980

673 Abbreviations: WLHIV-People living with HIV, LTBI-Latent Tuberculosis Infection, RR-Relative Risk

674 * LTBI diagnosis determined by 2x increase of frequency of IFNγ+CD4+ cells after stimulation with Mtb antigens over control


675 ** Includes one participant whose pre-pregnancy sample was unevaluable

676 *** Up to six months after delivery


677 [^] Samples collected up to six months before date of conception

678


A




B




C




D






E




F













Figure 6









Figure 8

	Pre-pregnancy	1 st Trimester	2 nd trimester	3 rd trimester	postpartum
Mtb-specific T-cells					
CD4+	↔	↔	↓	↓↓↓	↔
CD8+	↓↓↓	↓↓	↑↑	↑	↓↓
Mitogen stimulated T-cells					
CD4+	↔	↔	↔	↑↓	↓↑
CD8+	↔	↔	↑	↔	↔
Nonspecific T-cell activation					
Activated T-cells	↔	↓	↑↑	↑↑↑	↑